Skip to main content Skip to main navigation menu Skip to site footer
Reumatismo - The Italian Journal of Rheumatology

Editor-in-Chief: M.A. Cimmino, Genova, Italy | eISSN 2240-2683

  • About the Journal
  • Publication Ethics
  • Editorial Board
  • Current Issue
  • Early Access
  • Archives
  • Special Issues
    • Overview
  • Register
  • Login
  • Search
  • Contacts
  • News
1.0
Impact Factor 2024
1.7
CiteScore 2024
1.0
Impact Factor 2024
1.7
CiteScore 2024
Submit
an article
  1. Home /
  2. Search

Search

Advanced filters
Published After
Published Before

Search Results

##search.searchResults.foundPlural##
  • PO:08:113 | Shaping rheumatoid arthritis treatment: clinical and demographic drivers of tsDMARDs versus bDMARDs prescription post-EMA pronouncement on JAK inhibitors - insights from the AMBI-RA study Riccardo Bertola1, Beatrice Maranini1, Carlo Garaffoni1, Maria Pozzuto1, Anna Laura Riva Cambrino1, Alessandro Spinelli1, Letizia Mamprin1, Federico Agostini1, Martina Di Nunzio1, Marcello Govoni1, Alessandra Bortoluzzi1, Ettore Silvagni1 | 1Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Italy

    Società Italiana di Reumatologia
    25-11-2025
    https://doi.org/10.4081/reumatismo.2025.2139
    155
  • PO:13:188 | Menstrual alterations among women with rheumatoid arthritis: a comparative study across treatment modalities with focus on JAK inhibitors Angelica Napoletano1, Francesca Arezzo2, Marco Fornaro1, Giuseppe Lopalco1, Gennaro Cormio2, Vincenzo Venerito1, Florenzo Iannone1. | 1University of Bari, Rheumatology Unit Department of Precision and Regenerative Medicine, Jonica Area, Bari; 2Gynecologic Oncology, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy.

    Società Italiana di Reumatologia
    25-11-2025
    https://doi.org/10.4081/reumatismo.2025.2029
    306
  • PO:07:095 | Clinical impact of therapeutic modification following changes in AIFA reimbursement criteria for JAK inhibitors in patients with RA in remission/low disease activity: analysis of the multicenter JAK-SWAP RER study in Emilia-Romagna Marta Raschella1, Giulia Furia1, Martina Di Nunzio1, Francesco Luca Renzullo2, Francesco Girelli2, Federica Pignatti3, Francesco Ursini3, Licia Vultaggio4, Pierluigi Cataleta4, Elena Bravi5, Eugenio Arrigoni5, Francesca Bergossi6, Enrica Vandelli7, Massimo Reta6|7, Viola Magnani8, Andreina Manfredi8|9, Giuseppe Germanò8, Alessandra Bortoluzzi1, Marcello Govoni1, Ettore Silvagni1 | 1Unità Operativa Complessa di Reumatologia, Dipartimento di Scienze Mediche, Università degli Studi di Ferrara e Azienda Ferrara; 2UOS Reumatologia, Ospedale GB Morgagni, Forlì; 3UOC Reumatologia, Istituto ortopedico Rizzoli, Bologna; 4UO Reumatologia, AUSL Romagna Ospedale di Ravenna; 5UO Reumatologia, Azienda USL di Piacenza; 6Reumatologia Osp. Maggiore, Bologna; 7UO Medicina Interna ad Indirizzo Reumatologico Interaziendale SC AUSL Bologna, IRCCS Policlinico di SantOrsola, Bologna; 8U.O Reumatologia, Santa Maria Nuova di Reggio Emilia; 9Università degli studi di Modena e Reggio Emilia, Italy

    Società Italiana di Reumatologia
    25-11-2025
    https://doi.org/10.4081/reumatismo.2025.2135
    151
  • PO:06:081 | Safety of JAK inhibitors compared to non-TNF-targeted biologic therapies in rheumatoid arthritis patients who are inadequate responders to TNF inhibitors Lorenzo Di Luozzo1, Alessandro Giollo1, Mariangela Salvato1, Francesca Frizzera1, Kiren Khalid1, Margherita Zen1, Andrea Doria1 | 1Azienda ospedaliera universitaria di Padova, unità di Reumatologia, Padova, Italy

    Società Italiana di Reumatologia
    18-03-2026
    https://doi.org/10.4081/reumatismo.2025.2298
    32
  • PASSing to the patient side: early achieving of an acceptable symptom state in patients with rheumatoid arthritis treated with Janus kinase inhibitors

    Cristina Garufi, Silvia Mancuso, Fulvia Ceccarelli, Letizia Caruso, Cristiano Alessandri, Manuela Di Franco, Roberta Priori, Valeria Riccieri, Rossana Scrivo, Simona Truglia, Fabrizio Conti, Francesca Romana Spinelli
    05-11-2024
    https://doi.org/10.4081/reumatismo.2024.1725
    2666
    PDF: 397
  • CO:10:3 | Clinical response to JAK inhibitors or non-TNFi-targeted biologicals according to synovial tissue characteristics in patients with difficult-to-treat rheumatoid arthritis Mariangela Salvato1, Alessandro Giollo1, Francesca Frizzera1, Kiren Khalid1, Lorenzo Di Luozzo1, Maria Capita1, Marianna Tamussin1, Carlo Garaffoni2, Marny Fedrigo3, Annalisa Angelini3, Ettore Silvagni2, Andrea Doria1. | 1Rheumatology Unit, Department of Medicine - DIMED, University of Padova; 2Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna; 3Cardiovascular Pathology, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Italy

    Società Italiana di Reumatologia
    25-11-2025
    https://doi.org/10.4081/reumatismo.2025.1992
    141
  • Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: where do we stand and what may be the future?

    Beatrice Maranini, Roberta Foti, Moustapha Taha, Veronica Venturelli, Andrea Lo Monaco, Marcello Govoni
    29-01-2025
    https://doi.org/10.4081/reumatismo.2025.1754
    2246
    PDF: 434
    SUPPLEMENTARY MATERIAL: 166
  • Small molecules in idiopathic inflammatory myopathies: a systematic review and a multicenter case series about Janus kinase inhibitors and apremilast

    Chiara Rizzo, Silvia Grazzini, Edoardo Conticini, Hector Chinoy, Roberto D’Alessandro, Federica Camarda, Luca Cantarini, Bruno Frediani, Giuliana Guggino, Lidia La Barbera
    13-01-2025
    https://doi.org/10.4081/reumatismo.2025.1718
    1969
    PDF: 307
    SUPPLEMENTARY MATERIAL: 158
  • Baricitinib in polymyalgia rheumatica and giant cell arteritis: report of six cases

    Dario Camellino, Christian Dejaco, Franco Martini, Renzo Cosso, Gerolamo Bianchi
    28-10-2024
    https://doi.org/10.4081/reumatismo.2024.1796
    2123
    PDF: 476
  • PO:36:252 | Long-Term Outcomes of Patients with Takayasu Arteritis in the Era of Biological Agents: a Multicenter International Study Alessandro Tomelleri1, Durga Prasanna Misra2, Fatma Alibaz-Oner3, Chiara Marvisi4, Chiara Calabrese1, Upendra Rathore2, Aysegul Avcu3, Adele Del Giudice4, Elisabetta Olivi4, Caterina Ricordi4, Corrado Campochiaro1, Elena Baldissera1, Marco Matucci-Cerinic1, Haner Direskeneli3, Carlo Salvarani4, Lorenzo Dagna1 | 1IRCCS Ospedale San Raffaele, Unità di Immunologia, Reumatologia, Allergologia e Malattie Rare Milano, Italy; 2Sanjay Gandhi Postgraduate Institute of Medical Sciences SGPGIMS, Clinical Immunology and Rheumatology Lucknow Country, India; 3Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology Istanbul, Turkey; 4Azienda USL-IRCCS di Reggio Emilia, Unità di Reumatologia Reggio Emilia, Italy

    Società Italiana di Reumatologia
    18-03-2026
    https://doi.org/10.4081/reumatismo.2025.2389
    21
  • Sudden improvement of alopecia universalis and psoriatic arthritis while receiving upadacitinib: a case-based review

    Carlo Perricone, Roberto Dal Pozzolo, Giacomo Cafaro, Santina Calvacchi, Lorenza Bruno, Francesco Tromby, Anna Colangelo, Roberto Gerli, Elena Bartoloni
    25-10-2024
    https://doi.org/10.4081/reumatismo.2024.1685
    2410
    PDF: 714
  • CO:05:4 | Natural language processing reveals demographic features, comorbidities, and clinical domains to predict treatment longevity of b/tsDMARDs in psoriatic arthritis Antonio Tonutti1|2, Pierandrea Morandini3, Cosimo Faeti3, Nicoletta Luciano1|2, Saverio D'Amico3, Victor Savevski3, Carlo Selmi1|2 | 1Department of Biomedical Sciences, Humanitas University Pieve Emanuele, Milan, Italy; 2Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital Rozzano, Milan, Italy; 3Artificial Intelligence Unit, IRCCS Humanitas Research Hospital Rozzano, Milan, Italy

    Società Italiana di Reumatologia
    18-03-2026
    https://doi.org/10.4081/reumatismo.2025.2275
    22
  • PO:02:024 | Development of anti-drug antibodies in patients with peripheral and/or axial spondyloarthritis treated with infliximab or adalimumab: a monocentric cross-sectional study Gabriele Amati1, Gilda Sandri1|2, Alessandra Melegari3, Benedetta Bongiovanni1|2, Giovanni Ciancio2, Martina Orlandi1|2, Ottavio Secchi1, Dilia Giuggioli1|2 | 1Struttura complessa di Reumatologia, Azienda Ospedaliero-Universitaria Policlinico di Modena; 2Cattedra di Reumatologia, Università degli studi di Modena e Reggio Emilia; 3Dipartimento di medicina di laboratorio, Ospedale di Baggiovara, AUSL di Modena, Italy

    Società Italiana di Reumatologia
    25-11-2025
    https://doi.org/10.4081/reumatismo.2025.2126
    149
  • PO:01:006 | Increased risk of cancer recurrence or mortality associated with DMARDs? Laura Scagnellato1, Giacomo Cozzi1, Mariagrazia Lorenzin1, Mariangela Salvato1, Alessandro Giollo1, Bernd Raffeiner1, Antonia Calligaro1, Teresa Del Ross1, Sara Bindoli1, Margherita Zen1, Paolo Sfriso1, Andrea Doria1, Roberta Ramonda1. | 1UOC Reumatologia, Dipartimento di Medicina dei Sistemi DIMED, Ospedale Università di Padova, Padova, Italy.

    Società Italiana di Reumatologia
    25-11-2025
    https://doi.org/10.4081/reumatismo.2025.2003
    160
  • Effectiveness and safety profile of tofacitinib and baricitinib in rheumatoid arthritis patients: results from a 24-month real-life prospective study in Southern-Italy

    M. Tasso, N. Bertolini, E. Mostacciuolo, S. Passavanti, J.M.E. Luppino, A. Del Puente, R. Peluso, F. Santelli, R. Scarpa, L. Costa, F. Caso
    29-12-2022
    https://doi.org/10.4081/reumatismo.2022.1511
    2168
    PDF: 1000
1 - 15 of 15 items
Make a Submission

authors

FOR AUTHORS
  • ARTICLE PROCESSING CHARGE
  • Guide for Authors
  • Benefits for Authors
  • How to write a scientific paper
  • How to write a Review article

reviewers

FOR REVIEWERS
  • Benefits for Reviewers
  • How to review
  • Thanks to Reviewers

Categories

    • Abstract Book
    • Oral Communications - Day 1
    • Posters - Day 1
    • Oral Communications - Day 2
    • Posters - Day 2
    • Oral Communications - Day 3

indexing

INDEXING
  • PubMed
  • Scopus
  • Web of Science
  • Google Scholar
  • OpenAlex
  • Scilit
  • DOAJ
  • Società Italiana di Reumatologia
  • Analytics

linkedin

Follow Reumatismo on

Vol. 78 No. 1 (2026)
The Italian Society for Rheumatology guidelines for the treatment of patients with rheumatoid arthritis and interstitial lung disease
Chiara Crotti et al.
10 November 2025
Vol. 78 No. 1 (2026)
From anatomy to therapy: the historical journey to cortisone
Ernesto Damiani et al.
19 November 2025
Vol. 78 No. 1 (2026)
Computed tomography of interstitial lung disease in systemic sclerosis: dataset and deep learning model for pulmonary lesion segmentation
Amir M. Vahdani et al.
25 February 2026
Vol. 78 No. 1 (2026)
Macrophage activation syndrome and rapidly progressive lung disease as life-threatening manifestations of anti-MDA5 antibody disease. A case report
Filippo Gozzi et al.
22 December 2025

Keywords

Reumatismo - The Italian Journal of Rheumatology

is the Official Journal of the Italian Society of Rheumatology (SIR). Founded in 1949. Published online by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS.

pISSN: 0048-7449
eISSN: 2240-2683

Info

  • About
  • Editorial Board
  • News
  • Advertising

Info Submission

  • Submission
  • Guidelines For Authors
Themes by Openjournaltheme.com

© PAGEPress 2008-2026    •    PAGEPress® is a registered trademark property of PAGEPress srl, Italy    •    VAT: IT02125780185    •    Privacy